{"schema_version":"1","generated_at":"2026-10-28T08:40:18.234Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mohamad-sonbol","json_url":"https://www.findmykol.com/kol/mohamad-sonbol/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mohamad-sonbol","name":"Mohamad Sonbol","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Scottsdale","state":"AZ","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1578904173","orcid":"0000-0002-6931-242X","openalex":"A5059366804"},"summary":"Mohamad Sonbol is an Oncology physician. OpenAlex indexes 319 publications with 4,251 citations (h-index 34); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":319,"cited_by_count":4251,"h_index":34,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04660760","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Academic and Community Cancer Research United","source_url":"https://clinicaltrials.gov/study/NCT04660760","trial_url":"https://www.findmykol.com/trial/NCT04660760"}],"source":"trials"},"payments":{"company_count":5,"program_years":{"first":2021,"last":null},"rows_total":6,"shown":3,"withheld":3,"rows":[{"payer":"Bayer Healthcare Pharmaceuticals Inc.","program_year":2025,"amount_usd":2100,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1578904173"},{"payer":"Boehringer Ingelheim Pharmaceuticals, Inc.","program_year":2025,"amount_usd":1850,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1578904173"},{"payer":"Tempus AI, Inc","program_year":2025,"amount_usd":127.25,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1578904173"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1578904173","source":"payments"},"prescribing":{"data_year":2024,"areas_total":8,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":74.2,"classes_total":8,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":33.7,"drugs":[{"name":"Nivolumab","share_pct":51.6},{"name":"Pembrolizumab","share_pct":48.4}],"max_beneficiaries":34},{"class":"CD38-directed Cytolytic Antibody","setting":"administered","share_pct":26.1,"drugs":[{"name":"Daratumumab","share_pct":100}],"max_beneficiaries":58}]},{"area":"Metabolism & gastrointestinal","share_pct":17.8,"classes_total":5,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":14.7,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":42},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":2.9,"drugs":[{"name":"Palonosetron hcl","share_pct":49.4},{"name":"Ondansetron hydrochloride","share_pct":46.5},{"name":"Ondansetron Hcl","share_pct":4.1}],"max_beneficiaries":68}]},{"area":"Musculoskeletal","share_pct":3.6,"classes_total":1,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":3.6,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":15}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer","year":2025,"journal":"Cells","source_url":"https://doi.org/10.3390/cells14030161","status":"verified"},{"title":"DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.24.00410","status":"verified"},{"title":"Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab","year":2023,"journal":"JAMA Network Open","source_url":"https://doi.org/10.1001/jamanetworkopen.2023.0400","status":"verified"},{"title":"Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience","year":2023,"journal":"JCO Precision Oncology","source_url":"https://doi.org/10.1200/po.22.00706","status":"verified"},{"title":"Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting","year":2023,"journal":"European Journal of Cancer","source_url":"https://doi.org/10.1016/j.ejca.2023.113433","status":"verified"}],"source":"works"},"contact":{"address_1":"13400 E SHEA BLVD","city":"Scottsdale","state":"AZ","zip":"85259","phone":"480-301-8000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1578904173","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":3,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-09-03","provider_certified":"2020-09-03","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}